TECH · 10-Q/A · 2026Q3 · Full report

Balance Sheet and Liquidity

BIO-TECHNE Corp · 2026-11-12 · Importance 69 · Surprise 64 · From source text

Cash and cash equivalents were $350.0 million at September 30, 2026, up from $264.7 million at June 30, 2026. The Company had $800.0 million available under its revolving line of credit, which matures August 31, 2027, and did not draw on the facility during the quarter. Operating cash flow was $73.1 million in the first quarter of fiscal 2027, compared with $27.6 million in the prior-year quarter, primarily because of the timing of payments on operating assets and liabilities.

Key facts

• Bio-Techne generated $73.1 million of operating cash in the first quarter of fiscal 2027, compared with $27.6 million in the first quarter of fiscal 2026; the increase primarily reflected timing of payments on operating assets and liabilities. source
• BIO-TECHNE's cash and cash equivalents increased from $264.712 million at June 30, 2026 to $350.036 million at September 30, 2026. source
• BIO-TECHNE reported $73.113 million in net cash provided by operating activities for the quarter ended September 30, 2026. source
• Cash and cash equivalents were $350.0 million at September 30, 2026, compared with $264.7 million at June 30, 2026. source
• Management expects Bio-Techne can meet operating, facility-expansion, capital-addition, and dividend cash and working-capital needs for at least the next 12 months using available cash, operating cash flow, and remaining revolving credit. source
• BIO-TECHNE had $200.0 million outstanding under its Credit Agreement as of September 30, 2026 and June 30, 2026. source
• BIO-TECHNE stated that legal matters could materially adversely affect its consolidated earnings, financial position, or cash flows. source
• Bio-Techne received $36.2 million from stock-option exercises in the first quarter of fiscal 2027, compared with $23.5 million in the first quarter of fiscal 2026. source

Impact estimates